
|Articles|January 1, 2008
Updated Disease Management Guidelines Impact Investment Perspectives
Disease management programs don't come cheap, but thanks to industry collaboration, purchasers are increasingly learning how to assess the business case for these programs.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
3
7 takeaways from the MHE webinar on PBM reform and transparency
4
What employees may miss when they buy drugs directly online
5























